Tel: +49 30 468 14531
Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity†
Version of Record online: 22 APR 2011
Copyright © 2010 UICC
International Journal of Cancer
Volume 129, Issue 1, pages 245–255, 1 July 2011
How to Cite
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K.-H. and Zopf, D. (2011), Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int. J. Cancer, 129: 245–255. doi: 10.1002/ijc.25864
Potential conflicts of interest: SMW, LA, GS, KHT and DZ are currently employees of the Bayer HealthCare organisation.
- Issue online: 26 APR 2011
- Version of Record online: 22 APR 2011
- Accepted manuscript online: 17 DEC 2010 11:14AM EST
- Manuscript Accepted: 5 NOV 2010
- Manuscript Received: 27 APR 2010
Additional Supporting Information may be found in the online version of this article.
|IJC_25864_sm_suppfig01.eps||813K||Supporting Information Figure 1|
|IJC_25864_sm_suppfig02.eps||1000K||Supporting Information Figure 2|
|IJC_25864_sm_suppfig03.eps||973K||Supporting Information Figure 3|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.